Seres Therapeutics (MCRB) Operating Leases (2019 - 2025)
Historic Operating Leases for Seres Therapeutics (MCRB) over the last 7 years, with Q3 2025 value amounting to $75.3 million.
- Seres Therapeutics' Operating Leases fell 1164.94% to $75.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year decrease of 1164.94%. This contributed to the annual value of $83.0 million for FY2024, which is 947.72% down from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' Operating Leases is $75.3 million, which was down 1164.94% from $78.0 million recorded in Q2 2025.
- Seres Therapeutics' Operating Leases' 5-year high stood at $107.9 million during Q4 2022, with a 5-year trough of $9.2 million in Q1 2021.
- Moreover, its 5-year median value for Operating Leases was $80.5 million (2025), whereas its average is $65.0 million.
- Per our database at Business Quant, Seres Therapeutics' Operating Leases tumbled by 3634.73% in 2021 and then soared by 50108.03% in 2022.
- Over the past 5 years, Seres Therapeutics' Operating Leases (Quarter) stood at $18.0 million in 2021, then soared by 501.08% to $107.9 million in 2022, then dropped by 15.09% to $91.7 million in 2023, then dropped by 9.48% to $83.0 million in 2024, then dropped by 9.2% to $75.3 million in 2025.
- Its Operating Leases was $75.3 million in Q3 2025, compared to $78.0 million in Q2 2025 and $80.5 million in Q1 2025.